I give Niagen Bioscience, Inc. a hold rating. The company has a cash-rich balance sheet with no debt and high-quality earnings. Shareholders have already faced 47.5% dilution since 2016, and there ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Arcus Biosciences (RCUS): Losses Widen 26% Annually, Revenue Growth Projections Test Bullish Outlook
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
TuHURA Biosciences remains a high-risk investment due to severe cash constraints and imminent dilution risk despite progress in its immunotherapy pipeline. HURA's phase 3 trial for IFx-Hu2.0 in ...
Investing.com - H.C. Wainwright lowered its price target on Lexaria Bioscience (NASDAQ:LEXX) to $4.00 from $5.00 on Tuesday, while maintaining a Buy rating on the stock. Currently trading at $0.90, ...
Coherus Biosciences Inc (NASDAQ:CHRS) just announced that it has kicked off a public offering that will se it unload $125 million worth of its common stock, alongside an additional grant to the ...
Detailed price information for Dare Bioscience Inc (DARE-Q) from The Globe and Mail including charting and trades.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results